OBJECTIVES: to estimate the tangible savings generated when there is a joint effort between Pharmacist and Physician METHODS: observational descriptive study. Population: patient records belonging to an IPS Bogota, diagnosed with Osteoporosis in parenteral drug therapy with bisphosphonates (Zoledronic Acid 5mg Ibandronic Acid 3mg). Observation period: June 2012 to June 2013 (n=161). The Pharmacist identified patients with non-pertinence to parenteral bisphosphonate. Non-pertinence was defined when: the patients had osteopenia (no additional risk factors), had renal function <35 ml/min, no previous scaling with oral medications and when were men with diagnosis of osteoporosis. Finally, the Physician defined the behavior to follow (changing drug therapy). Analysis: were used absolute and relative frequencies, measures central tendency and dispersion. Treatment direct costs were quantified before and after assessment by the Pharmacist and the Physician. The statistical software SPSS 21 license under the CES University was used. RESULTS: pharmacist non-pertinence identified in 34% (54/161) of patients, of which, the Physician agreed in 70% of cases (38/54). The 39% of patients switched to oral bisphosphonates (Calcium Alendronate 70mg, Strontium Ranelate 2mg, Risedronate 35mg), 40% Calcium and Vitamin D3 and 21% left without medication. Given that patients were pretreated with Zoledronic Acid 5mg (25/38) or Ibandronic Acid 3mg (13/38), this conduct involved a decreased 18% a year later, with savings/year $ 9,164  (considering only the value of the drugs)